BIOLOGICAL INTERACTIONS OF EXTRACELLULAR VESICLES CONTRIBUTING TO METASTASIS OF BREAST CANCER AND OSTEOSARCOMA
Raluca Ghebosu, PhD Candidate
Australian Institute for Bioengineering and Nanotechnology
University of Queensland, Brisbane, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Queensland, Australia | October 2024
Raluca Ghebosu graduated from the University of Queensland with a Bachelor of Arts/Bachelor of Science with majors in Japanese and Biomedical Science (2018-2021). She then completed her Bachelor of Science (Honours) with the School of Biomedical Sciences at the University of Queensland in 2022, before pursuing a PhD with A/Prof. Joy Wolfram at the Australian Institute for Bioengineering and Nanotechnology.
Raluca is currently exploring the complex biological interactions of extracellular vesicles, with the goal of understanding how they can contribute to the metastasis of breast cancer and osteosarcoma. She will do this by uncovering how extracellular vesicles from breast cancer and osteosarcoma cells allow the cancer cells to evade the immune system and avoid being detected by Natural Killer cells. By shedding light on the complex role of extracellular vesicles in cancer metastasis she hopes to revolutionise nanoparticle and cell-based cancer treatments.
Since beginning her PhD in 2023, Raluca has published two first author and two co-author manuscripts in high-ranking journals, including a first author paper in the premier journal of her field, Journal of Extracellular Vesicles (IF: 15.5), and has gained over 500 citations across her publications. She has presented her work to various audiences including scientists, clinicians and consumers and is a University of Queensland, 2024 3 Minute Thesis finalist. Raluca is also involved with the Wonder of Science Outreach program that promotes scientific inquiry and engagement to school-aged students across Queensland. Raluca hopes to continue being an advocate for STEM education and sharing her work with consumers and the broader scientific community
You Might also like
-
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
-
Outcomes of Corneal Allergenic Intrastromal Ring Segment (CAIRS) Surgery
Dr David Gunn is an ophthalmologist specialising in cornea, cataract, and refractive surgery at the Queensland Eye Institute and Focus Vision in Brisbane, Queensland. His journey into ophthalmology began during medical school, inspired by a mentor. His current research examines outcomes for patients undergoing Corneal Allergenic Intrastromal Ring Segment (CAIRS) surgery.
-
Supportive care for people living with or beyond cancer treatment
Dr Hannah Wardill is a Hospital Research Foundation Fellow and lead of the Supportive Oncology Research Group (SORG), in the School of Biomedicine, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI). She is an Executive Board Member of the Multinational Association for Supportive Care in Cancer / International Society for Oral Oncology (MASCC/ISOO) and Chair of both MASCC/ISOO Patient Partnership Committee & the Palliative Care Clinical Studies Collaborative (PaCCSC) Cancer Symptom Trials (Gut Dysfunction Node; supported by Cancer Australia).
https://orcid.org/0000-0001-8839-3512